Education
About Us
Working with TipRanks
Follow Us
Ascendis Pharma (ASND)
NASDAQ:ASND
ASND Stock Chart & Stats
Day’s Range― - ―
52-Week Range$118.03 - $214.71
Previous CloseN/A
Volume129.18K
Average Volume (3M)417.97K
Market Cap
$12.77B
Enterprise Value$10.78B
Total Cash (Recent Filing)$494.05M
Total Debt (Recent Filing)$792.53M
Price to Earnings (P/E)―
Beta0.77
Next Earnings
Nov 13, 2025EPS Estimate
-0.38Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.95
Shares Outstanding61,151,463
10 Day Avg. Volume427,329
30 Day Avg. Volume417,966
Financial Highlights & Ratios
PEG Ratio0.86
Price to Book (P/B)-72.81
Price to Sales (P/S)21.17
P/FCF Ratio-25.02
Enterprise Value/Market Cap0.84
Enterprise Value/Revenue24.91
Enterprise Value/Gross Profit29.15
Enterprise Value/Ebitda-135.13
Forecast
1Y Price Target
$250.44Price Target Upside19.34% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering16
Bulls Say, Bears Say
Bulls Say
Clinical EfficacyYorvipath demonstrates a strong statistical significance in its Phase 3 study, which is a positive indicator of its efficacy.
Growth PotentialThe chronic hypoparathyroidism market is a significant $10B+ market, positioning ASND as a leader with considerable growth potential.
Market PositionYorvipath is seen as having the best clinical profile in the treatment of hypoparathyroidism according to discussions with a key opinion leader.
Bears Say
Adverse EffectsConcerns about prolonged hypercalcemia in the competitor's treatment could pose a risk of kidney damage.
Competitive ChallengesMBX data shows efficacy, which could pose a competitive challenge to ASND's Yorvipath.
Data ReliabilityThe high placebo response rate in the competitor's study raises questions about the reliability of the data.
Ascendis Pharma News
ASND FAQ
What was Ascendis Pharma’s price range in the past 12 months?
Ascendis Pharma lowest stock price was $118.03 and its highest was $214.71 in the past 12 months.
What is Ascendis Pharma’s market cap?
Ascendis Pharma’s market cap is $12.77B.
When is Ascendis Pharma’s upcoming earnings report date?
Ascendis Pharma’s upcoming earnings report date is Nov 13, 2025 which is in 36 days.
How were Ascendis Pharma’s earnings last quarter?
Ascendis Pharma released its earnings results on Aug 07, 2025. The company reported -$0.953 earnings per share for the quarter, beating the consensus estimate of -$1.495 by $0.542.
Is Ascendis Pharma overvalued?
According to Wall Street analysts Ascendis Pharma’s price is currently Undervalued.
Does Ascendis Pharma pay dividends?
Ascendis Pharma does not currently pay dividends.
What is Ascendis Pharma’s EPS estimate?
Ascendis Pharma’s EPS estimate is -0.38.
How many shares outstanding does Ascendis Pharma have?
Ascendis Pharma has 61,151,463 shares outstanding.
What happened to Ascendis Pharma’s price movement after its last earnings report?
Ascendis Pharma reported an EPS of -$0.953 in its last earnings report, beating expectations of -$1.495. Following the earnings report the stock price went up 0.599%.
Which hedge fund is a major shareholder of Ascendis Pharma?
Currently, no hedge funds are holding shares in ASND
Ascendis Pharma Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$250.44 (19.34% Upside)
$250.44 (19.34% Upside)
Blogger Sentiment
Bullish
ASND Sentiment 100%
Sector Average 72%
Sector Average 72%
Hedge Fund Trend
Increased
By 862.8K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Positive
Last 7 Days ▼ 2.4%
Last 30 Days ▲ 8.7%
Last 30 Days ▲ 8.7%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Positive
20 days / 200 days
Momentum
50.82%
12-Months-Change
Fundamentals
Return on Equity
357.68%
Trailing 12-Months
Asset Growth
57.13%
Trailing 12-Months
Company Description
Ascendis Pharma
Ascendis Pharma is a biopharmaceutical company focused on transforming the lives of patients through innovative therapies. The company operates primarily in the sectors of endocrinology, oncology, and rare diseases, leveraging its proprietary TransCon technology platform to develop a pipeline of product candidates that address unmet medical needs. Ascendis Pharma's core products include TransCon Growth Hormone for growth hormone deficiency and TransCon PTH for hypoparathyroidism, among others, aimed at providing enhanced treatment options for patients.
ASND Earnings Call
Q2 2025
0:00 / 0:00
Earnings Call Sentiment|Positive
The earnings call reflected a strong performance for Ascendis Pharma with significant revenue growth, successful product launches, and strategic progress in their pipeline. While there are challenges related to currency impacts and patient conversion timelines, these are offset by the momentum in product adoption and regulatory advancements.View all ASND earnings summariesASND Stock 12 Month Forecast
Average Price Target
$250.44
▲(19.34% Upside)
Technical Analysis
BioMarin Pharmaceutical
―
Exelixis
―
Madrigal Pharmaceuticals
―
United Therapeutics
―
BridgeBio Pharma
―
Ownership Overview
―
Insiders
31.93% Mutual Funds
0.21% Other Institutional Investors
66.44% Public Companies and
Individual Investors